Real-world observations and impacts of Chinese herbal medicine for migraine: results of a registry-based cohort study

被引:1
|
作者
Lyu, Shaohua [1 ,2 ]
Zhang, Claire Shuiqing [2 ]
Zhang, Anthony Lin [2 ]
Guo, Xinfeng [1 ]
Hua, Rong [1 ]
Mao, Zhenhui [1 ]
Su, Qiaozhen [1 ]
Xue, Charlie Changli [1 ,2 ]
Sun, Jingbo [1 ,3 ,4 ]
机构
[1] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China
[2] RMIT Univ, STEM Coll, China Australia Int Res Ctr Chinese Med, Melbourne, Vic, Australia
[3] State Key Lab Dampness Syndrome Chinese Med, Guangzhou, Peoples R China
[4] Guangdong Prov Key Lab Res Emergency TCM, Guangzhou, Peoples R China
关键词
migraine; Chinese herbal medicine; real-world; cohort study; preferences and values; clinical expertise; QUALITY-OF-LIFE; HEADACHE SOCIETY; DOUBLE-BLIND; ALTERNATIVE MEDICINE; INTERNATIONAL BURDEN; CANADIAN HEADACHE; EPISODIC MIGRAINE; TIANSHU CAPSULE; RISK-FACTORS; RAT MODEL;
D O I
10.3389/fphar.2024.1330589
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Migraine is a prevalent, recurrent condition with substantial disease burden. Chinese herbal medicine (CHM) has been used frequently for migraine in controlled clinical settings. This study is to summarise the characteristics of patients who seek clinical care in a tertiary Chinese medicine hospital in China; to gather their preferences and values of using CHM; to explore the effect of CHM for migraine and its comorbidities in a real-world setting, and to collect first-hand expertise of clinicians' practice pattern in prescribing CHM for migraine.Methods: This registry-based cohort study was prospectively conducted at Guangdong Provincial Hospital of Chinese Medicine from December 2020 to May 2022. Adult migraine patients seeking their initial anti-migraine clinical care at the hospital were consecutively recruited and followed up for 12 weeks. Practitioners specialised in headache management prescribed individualised treatments without research interference. Standardised case report forms were employed to gather information on patients' preferences and perspective of seeking clinical care, as well as to assess participants' migraine severity, comorbidities, and quality of life, at 4-weeks intervals. Various analytical methods were utilised based on the computed data.Results: In this study, we observed 248 participants. Of these, 73 received CHM treatment for 28 days or longer. Notably, these participants exhibited a greater disease severity, compared to those treated with CHM for less than 28 days. Of the 248 participants, 83.47% of them expected CHM would effectively reduce the severity of their migraine, around 50% expected effects for migraine-associated comorbidities, while 51.61% expressing concerns about potential side effects. CHM appeared to be effective in reducing monthly migraine days and pain intensity, improving patients' quality of life, and potentially reducing comorbid anxiety, with a minimum of 28 days CHM treatment. Herbs such as gan cao, gui zhi, chuan xiong, fu ling, bai zhu, yan hu suo, etc. were frequently prescribed for migraine, based on patients' specific symptoms.Conclusion: CHM appeared to be beneficial for migraine and comorbid anxiety in real-world clinical practice when used continuously for 28 days or more.Clinical Trial Registration: clinicaltrials.gov, identifier ChiCTR2000041003.
引用
收藏
页数:24
相关论文
共 50 条
  • [1] Migraine patients visiting Chinese medicine hospital: Protocol for a prospective, registry-based, real-world observational cohort study
    Lyu, Shaohua
    Zhang, Claire Shuiqing
    Zhang, Anthony Lin
    Sun, Jingbo
    Xue, Charlie Changli
    Guo, Xinfeng
    PLOS ONE, 2022, 17 (03):
  • [2] Real-World Effects of Chinese Herbal Medicine for Idiopathic Membranous Nephropathy (REACH-MN): Protocol of a Registry-Based Cohort Study
    Yang, Lihong
    Chen, Xueyin
    Li, Chuang
    Xu, Peng
    Mao, Wei
    Liang, Xing
    Zuo, Qi
    Ma, Weizhong
    Guo, Xinfeng
    Bao, Kun
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [3] Comparison of effectiveness of denosumab versus bisphosphonates in a registry-based, real-world cohort study
    Everts-Graber, Judith
    Bonel, Harald
    Lehmann, Daniel
    Gahl, Brigitta
    Hauselmann, HansJorg
    Studer, Ueli
    Ziswiler, Hans-Rudolf
    Reichenbach, Stephan
    Lehmann, Thomas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 5 - 6
  • [4] Comparison of anti-fracture effectiveness of denosumab versus bisphosphonates in a registry-based, real-world cohort study
    Everts-Graber, J.
    Bonel, H.
    Lehmann, D.
    Gahl, B.
    Hauselmann, H. J.
    Studer, U.
    Hr, Ziswiler
    Reichenbach, S.
    Lehmann, T.
    SWISS MEDICAL WEEKLY, 2022, 152 : 2S - 2S
  • [6] Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland
    Koskivirta, I
    Ruotsalainen, J.
    Kurki, S.
    Lakkakorpi, P.
    Salminen-Mankonen, H.
    Pirila, L.
    Harvima, R.
    Palomaki, A.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 (05) : 549 - 555
  • [7] Does Chinese herbal medicine (CHM) reduce colorectal adenoma (CRA) recurrence: protocol of a registry-based, cohort study and a qualitative interview
    Cheng, Yi
    Di, Yuan Ming
    Zhang, Anthony Lin
    Hu, Peixin
    Mo, Jiahao
    Zhang, Haiyan
    Xue, Charlie Changli
    Zhang, Beiping
    BMJ OPEN, 2023, 13 (11):
  • [8] REGISTRY-BASED STUDIES IN PRACTICE: ENHANCING REAL-WORLD EVIDENCE GENERATION IN RARE DISEASE AND PERSONALIZED MEDICINE
    Saragoussi, D.
    Rouleau, A.
    Ruzafa, Cid J.
    VALUE IN HEALTH, 2022, 25 (01) : S276 - S276
  • [9] Identification and characterization of migraine in pregnancy: A Norwegian registry-based cohort study
    Mitter, Vera R.
    Lupattelli, Angela
    Bjork, Marte-Helene
    Nordeng, Hedvig M. E.
    CEPHALALGIA, 2024, 44 (04)
  • [10] COMPARISON OF FRACTURE REDUCTION EFFECTIVENESS OF DENOSUMAB VS. ALENDRONATE, IBANDRONATE AND ZOLEDRONATE IN A REGISTRY-BASED, REAL-WORLD COHORT STUDY
    Everts-Graber, J.
    Bonel, H.
    Lehmann, D.
    Gahl, B.
    Hauselmann, H. J.
    Studer, U.
    Ziswiler, H. R.
    Reichenbach, S.
    Lehmann, T.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S219 - S219